Breakthrough In Vivo Gene Therapy Offers Hope for Parkinson's Disease Sufferers

The video discusses the first in vivo gene therapy for Parkinson's disease, led by Dr. Michael Kaplit. The procedure involves infusing viral particles with a human gene to produce GABA, aiming to relieve symptoms. Nathan Klein, the first patient, shared his positive experience post-procedure. The trial is in phase one, focusing on safety. Despite FDA approval, some experts criticize the lack of prior evidence in monkeys. Klein was awake during the surgery, which involved drilling into his skull. Current medical therapies often become ineffective or cause side effects over time.

What concerns did experts have regarding the surgery?

• Lack of evidence in monkeys

• High cost of the procedure

• Patient's age

• Duration of the trial

Describe Nathan Klein's experience during the procedure.

• He was asleep

• He felt no pain

• He was awake and uncomfortable

• He was nervous but calm